- Learn More
Paul, Weiss is widely recognized as having one of the nation’s preeminent securities litigation and regulatory practices. For two decades, our lawyers have guided global corporations and financial institutions through a series of “bet-the-company” securities-related crises, consistently reducing or eliminating their most damaging claims and negotiating favorable resolutions.
- Securities Litigation
- Financial Institutions
- Mergers & Acquisitions Litigation
- White Collar & Regulatory Defense
- Mergers & Acquisitions
- Capital Markets
- Susanna M. Buergel
- Jessica S. Carey
- Geoffrey R. Chepiga
- Lewis R. Clayton
- Andrew J. Ehrlich
- Brad S. Karp
- Daniel J. Kramer
- Gregory F. Laufer
- Raphael M. Russo
- Audra J. Soloway
- Daniel S. Sinnreich
- Michael E. Donohue
- Robert J. O'Loughlin
The explosive growth in Special Purpose Acquisition Companies (SPACs) is starting to generate significant amounts of litigation. In this alert, we survey notable SPAC litigation trends and recommend what SPAC sponsors, directors and officers can do preemptively to minimize litigation exposure.
Paul, Weiss achieved a major victory for Morgan Stanley when District Judge Paul G. Gardephe of the Southern District of New York dismissed a class action against several financial institutions that participate in the auction and trading of securities issued by the U.S. Treasury.
Awards & Recognition
Paul, Weiss was recognized with a 2021 “Impact Case Award” by Benchmark Litigation as part of its annual U.S. awards program.
Paul, Weiss secured the dismissal of Securities Act claims against our clients, underwriters of an IPO by UK-based pigment maker Venator Materials PLC, when the New York Supreme Court dismissed a putative class action as time-barred.
In a decision likely spelling the end of the case, a magistrate judge recommended that a shareholder derivative action against 17 current or former directors and officers of Teladoc Health, Inc. be dismissed with prejudice. Paul, Weiss is defending the Teladoc defendants in the case.
As an update to our earlier alert, “Mitigating Securities Litigation Risks Related to the Coronavirus,” we look at key takeaways from the first two securities fraud class action filings related to COVID-19 disclosures and outline additional steps companies can take to mitigate the risks associated with COVID-19-linked shareholder litigation.
SEC Charges Company with COVID-19-Related Securities Fraud, Reaffirming its Focus on Public Statements and Disclosures Relating to COVID-19
The SEC recently brought its first enforcement action arising out of the COVID-19 pandemic. The action reaffirms the Commission’s laser focus on companies’ statements concerning, and responses to, the pandemic.
Federal District Court Determines That Pharmaceutical Company Has No Standalone Obligation to Disclose Interim FDA Feedback on Form 483
A federal district court dismissed a putative securities class action lawsuit against Nabriva Therapeutics and several of its officers alleging that the company had fraudulently misled investors about its prospects for getting FDA approval for its new drug, CONTEPO.
Paul, Weiss secured the dismissal of a putative securities class action brought against our clients Telefonaktiebolaget LM Ericsson and various Ericsson executives relating to Ericsson’s accounting for various long-term service contracts.
Paul, Weiss Wins Dismissal of Securities Claims Against CBS Lead Independent Director Arising From Former CEO’s Alleged Sexual Misconduct
Paul, Weiss secured a major victory for Bruce Gordon, the former lead independent director of the board of CBS Corporation, in a putative securities class action arising from former CEO and Chairman Leslie Moonves’ and others’ sexual misconduct.
The spread of coronavirus has disrupted global businesses and triggered severe U.S. stock market declines. These events raise the risk that shareholders will convert these stock drops into litigation. We address the securities litigation risks and suggest steps companies may decide to take to mitigate these risks.
Paul, Weiss secured the dismissal, with prejudice, of a putative securities class action brought against our client Oaktree Capital Management, L.P. relating to Oaktree’s investment in Tribune Media Company.
Paul, Weiss achieved another victory for Pretium Resources Inc. and two executives when the U.S. District Court for the Southern District of New York denied plaintiffs’ motion for leave to amend their complaint following dismissal of a securities class action alleging that Pretium had defrauded investors.
In CalPERS v. ANZ Securities, the Supreme Court ruled that the filing of a class action does not toll the Securities Act’s three-year statute of repose.
Paul, Weiss secured the dismissal of a putative securities class action against our client Meridian Bioscience, an Ohio-based life science company.